[A26-01] Lecanemab (early Alzheimer’s disease) – Addendum to Project A25-111
Last updated 19.02.2026
Project no.:
A26-01
Commission:
Commission awarded on 13.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adults with early Alzheimer’s disease who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology
- Patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer’s disease: Unchanged after addendum: added benefit not proven (based on the results of the relevant study)
- Patients with a clinical diagnosis of mild dementia due to Alzheimer’s disease and lecanemab as add-on therapy to acetylcholinesterase inhibitors: Unchanged after addendum: added benefit not proven (based on the results of the relevant study)
- Patients with a clinical diagnosis of mild dementia due to Alzheimer’s disease and lecanemab monotherapy: Unchanged after addendum: added benefit not proven (no relevant study)
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-01
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A25-111 | Lecanemab (early Alzheimer’s disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
19-02-2026 A G-BA decision was published.
G-BA documents on this decision